Haiyao Group: Avibactam Sodium API Obtains Approval Notice for Market Application

Haiyao Pharmaceutical announced that the company's Avibatan Sodium bulk drug has received the "Notice of Approval for Listing Application of Chemical Bulk Drugs". As of the date of the announcement, approximately 27.02 million yuan has been invested in this research and development project. This approval will enrich the company's bulk drug product pipeline, improve market competitiveness, and solidify the strategy of integrating raw materials and formulations. However, the production and sales of bulk drugs are affected by factors such as demand for finished formulations and market conditions, which may present uncertainties. Investors are reminded to pay attention to risks.